Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-861 (oveporexton) in narcolepsy type 1 with cataplexy
jRCT2051240083Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of oveporexton in narcolepsy type 1 (NT1) (3 arms), sponsored by Takeda. Primary endpoint: Change from baseline to Week 12 in mean sleep latency from the 4 Maintenance of Wakefulness Test (MWT) wake trials. Started Jul 2024; status: completed.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on jRCT2051240083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240083.